Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipelineDren Bio deep B-cell ...

Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio Inc. for $600 million upfront ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Northwestern Medicine investigators have uncovered new insights into how intercellular "glue" functions to enable ...

Our immune system works to fight infections immediately, but also maintain long-term immunity. Two waves of protection help ...

Sanofi to pay $600 million upfront payment to buy Dren Bio's bispecific myeloid cell engager, DR-0201: Paris Friday, March 21, 2025, 09:00 Hrs [IST] Sanofi and Dren Bio, Inc., a p ...

Sanofi (SNY) and Dren Bio, a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has ...

Findings show potential for new lipid-based delivery formulations as a platform technology for immunizationPhiladelphia, PA, ...

Halting the relentless march of so-called 'zombie cells' that drive aging and age-related diseases could be a step closer ...

CARGO Therapeutics (CRGX, Financials) saw its stock jump 18.9% pre-market to $4.52 on Wednesday after announcing it would ...